Cogent Biosciences Files New Drug Application For Bezuclastinib
Cogent Biosciences (NASDAQ:COGT) has filed a New Drug Application with the U.S. FDA for bezuclastinib, its drug candidate for Advanced Systemic Mastocytosis, supported by positive clinical trial results from the APEX key trial. The company aims to secure initial approvals by year-end 2026 and is also advancing another JAK2 V617F mutation-specific inhibitor.
Tickers: $COGT
Topics: biotech drug development FDA submission